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Abstract
The phosphatidylinositol 3-kinase–AKT–mammalian target of rapamycin (mTOR) pathway has been implicated in breast 
carcinogenesis. However, there has been no large-scale investigation of genetic variants in the mTOR pathway and breast 
cancer risk. We examined 28 847 single-nucleotide polymorphisms (SNPs) in 61 mTOR pathway genes in the African American 
Breast Cancer Epidemiology and Risk consortium of 3663 cases [1983 estrogen receptor-positive (ER+) and 1098 ER-negative 
(ER−)] and 4687 controls. Gene-level analyses were conducted using the adaptive rank truncated product (ARTP) test for 10 773 
SNPs that were not highly correlated (r2 < 0.8), and SNP-level analyses were conducted with logistic regression. Among genes 
that were prioritized (nominal P < 0.05, ARTP tests), associations were observed for intronic SNPs TSC2 rs181088346 [odds ratio 
(OR) of each copy of variant allele = 0.77, 95% confidence interval (CI) = 0.65–0.88 for all breast cancer] and BRAF rs114729114 
(OR = 1.53, 95% CI = 1.24–1.91 for all breast cancer and OR = 2.03, 95% CI = 1.50–2.76 for ER− tumors). For ER− tumors, intronic 
SNPs PGF rs11542848 (OR = 1.38, 95% CI = 1.15–1.66) and rs61759375 (OR = 1.34, 95% CI = 1.14–1.57) and MAPK3 rs78564187 (OR 
= 1.26, 95% CI = 1.11–1.43) were associated with increased risk. These SNPs were significant at a gene-wide level (Bonferroni-
corrected P < 0.05). The variant allele of RPS6KB2 rs35363135, a synonymous coding SNP, was more likely to be observed in 
ER− than ER+ tumors (OR = 1.18, 95% CI = 1.05–1.31, gene-wide Bonferroni-corrected P = 0.06). In conclusion, specific mTOR 
pathway genes are potentially important to breast cancer risk and to the ER negativity in African American women.
Introduction
African American (AA) women have the highest prevalence 
of obesity (58.6% with body mass index >30 kg/m2) (1) among 
racial/ethnic groups in the USA. AA women are also more likely 
to have central obesity than white women (2), which has been 
associated with hyperinsulinemia and insulin resistance, both 
of which are implicated in breast cancer (3). Among AA women, 
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the association of obesity with breast cancer risk may differ by 
tumor subtypes defined by receptor status, including estrogen 
receptor (ER) (4,5). Although research has suggested several 
biological pathways relevant to obesity (e.g. inflammation and 
hormonal factors), the mechanisms by which body size influ-
ences breast cancer risk are largely unclear (6). Because a key 
causal factor for obesity is positive energy imbalance, that is, 
energy intake being greater than expenditure, pathways related 
to energy signaling may be important to the underlying mecha-
nism behind the influence of obesity on breast cancer risk.
The phosphatidylinositol 3-kinase–AKT–mammalian target 
of rapamycin (mTOR) pathway can sense both cellular growth 
conditions and energy signaling (Figure 1). In cells with excess 
energy, adenosine monophosphate signals the mTOR complex 
1 (mTORC1), activating a variety of downstream responses 
including cell proliferation, angiogenesis and blockage of 
cell autophagy (7). In addition, mTORC2 receives signals from 
growth factors (e.g. glucose and insulin) and further stimulates 
AKT and mTORC1 (8). AKT1 and MTOR mutations are observed 
in breast cancer tumor tissue (9). Thus, the mTOR pathway may 
be important in breast carcinogenesis, and investigating genetic 
polymorphisms in this pathway may shed light on associations 
between obesity and breast cancer risk. To date, there are few 
studies examining the association of genetic variation in the 
mTOR pathway and breast cancer risk (10) and subtypes (10,11), 
and only a small number of single-nucleotide polymorphisms 
(SNPs) have been examined. Also, to our knowledge, no pub-
lished study has assessed this association among AA women. 
Here, we investigated the association of genetic variants in the 
mTOR pathway with breast cancer risk in a large sample of AA 
women. We examined the association of variants in genes in 
the mTOR pathway with overall breast cancer risk, as well as 
with ER-positive (ER+) and ER-negative (ER−) breast cancer risk 
separately because of potential differences in etiology related 
to obesity (4,5). We also investigated the association of variants 
with ER negativity in case-only analysis.
Methods
Study population
We included women with incident invasive breast cancer or ductal car-
cinoma in situ and controls with available DNA for genotyping in the 
African American Breast Cancer Epidemiology and Risk (AMBER) consor-
tium (12,13). The AMBER consortium pools data from four studies with 
large numbers of AA women: the Carolina Breast Cancer Study (CBCS), 
the Women’s Circle of Health Study (WCHS), the Black Women’s Health 
Study (BWHS) and the Multiethnic Cohort (MEC) Study. Briefly, the CBCS 
is a population-based case–control study of women aged 20–74  years 
in North Carolina conducted 1993–1996 (phase I) and 1996–2001 (phase 
2)  (14). Breast cancer cases were identified through the North Carolina 
Central Cancer Registry; controls were identified from Division of Motor 
Vehicle lists (age < 65) or from Health Care Financing Administration lists 
(age ≥ 65). Controls were frequency matched to cases on age in 5-year age 
groups. The current study also included participants from CBCS phase III, 
a case-only prospective study started in 2008. Home visits were conducted 
to collect information on breast cancer risk factors and to obtain biospeci-
mens. The WCHS is a case–control study of women aged 20–75 years that 
began in New York in 2003, subsequently expanded to New Jersey (15), 
and currently enrolling only AA participants in New Jersey. Breast can-
cer cases were identified through major hospitals in New York City and 
through the New Jersey State Cancer Registry. Controls were identified 
through random digit dialing and through community-based recruitment 
(16). Controls were frequency matched to cases on 5-year age group. Data 
on epidemiologic risk factors and samples for DNA analysis were obtained 
during home interviews (4). The BWHS is a prospective cohort study of 
59 000 AA women 21–69  years of age recruited from 17 states in 1995 
(17). Breast cancer diagnoses were self-reported on the biennial follow-
up questionnaires or identified through state cancer registries and the 
National Death Index. Approximately 27 000 BWHS participants provided 
saliva samples for DNA analysis. The MEC is a prospective study started 
in 1993–1996 that includes 16 594 AA women 45–75 years of age (18). Data 
were collected through questionnaires mailed at 5-year intervals; blood 
samples were obtained for DNA analysis. Cases were identified by link-
age to the Hawaii Tumor Registry, the Cancer Surveillance Program for Los 
Angeles County and the California State Cancer Registry. For BWHS and 
MEC cohorts, controls were selected among study participants who had 
not been diagnosed with breast cancer.
For all studies, ER status was based on immunohistochemistry results 
from hospital pathology records and/or cancer registry data. All partici-
pants were self-identified AA women. Each study obtained informed con-
sent from all participants and was approved by the relevant Institutional 
Review Boards.
Genotyping
DNA was isolated from blood in CBCS and MEC, from saliva obtained using 
Oragene kits in WCHS and from saliva obtained using a mouthwash-swish 
method in BWHS (19). A total of 61 candidate genes of the mTOR pathway 
were selected based on pathway information provided by BioCarta (20) 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) (Supplementary 
Table 1, is available at Carcinogenesis Online). The gene set included key 
proteins of the mitogen-activated protein kinases (MAPK) pathway, which 
can signal the mTOR pathway (10). Tag SNPs were selected based on link-
age disequilibrium (r2 ≥ 0.8) with minor allele frequency ≥10%, according 
to the haplotype structure of the Yoruban population in 1000 Genomes. 
Genotyping using the Illumina Human Exome Beadchip v1.1 with custom 
content was performed on samples from CBCS, WCHS and BWHS by the 
Center for Inherited Disease Research (CIDR). Genotypes were attempted 
for 6936 study subjects from the BWHS, CBCS and WCHS, and completed 
with call rate >98% for 6828 (3130 cases and 3698 controls). Prior to imputa-
tion, we omitted SNPs that were monomorphic, were positional duplicates, 
were on the Y chromosome, had a P value for Hardy–Weinberg equilibrium 
<1 × 10−4, had call rate <0.98, had >1 Mendelian errors in HapMap trios or 
had >2 discordant calls in duplicate samples. Imputation was performed 
at the University of Washington, Seattle, WA, using IMPUTE2 software 
and the 1000 Genomes Phase I reference panel (release date: 21 May 2011; 
December 2013 released haplotypes) (21). SNPs from the standard and cus-
tom content of the exome chip were used to impute the 1000 Genomes 
variants present with ≥2 minor alleles on the AFR and EUR panels. As the 
imputation backbone for this study was not as dense as typical genome-
wide association study chips, imputation quality metrics in regions with 
sparse coverage was lower than for genome-wide association study chips. 
However, 57% of all 1000 Genomes imputed variants within 60 kb of at 
least one genotyped SNP on our panel had r2 ≥ 0.5. Using the masking 
analysis in IMPUTE2 to compare imputed to true genotypes, that is, impu-
tation r2, variants with MAF ≥ 0.05 had median r2 = 0.93, and variants with 
MAF < 0.05 had median r2 = 0.53. For the MEC study, genetic data from 533 
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cases and 989 controls were already available, including Illumina Human 
1M-Duo chip data and SNPs imputed from 1000 Genomes. The imputed 
genotypes from the BWHS, CBCS and WCHS were combined with the 
imputed genotypes from MEC into a final data set. Variants were included 
in the combined data set if the allele frequencies in the two subsets dif-
fered by ≤0.15 or if the imputation r2 was ≥0.5 in either study. The cri-
terion of imputation r2 was more stringent than what was commonly 
used in genome-wide association study (r2 ≥ 0.2–0.3) (22,23). Subsequently, 
28 847 SNPs from the 61 mTOR pathway candidate genes entered statis-
tical analyses for this study (see Supplementary Material, is available at 
Carcinogenesis Online, for rsID and other information).
To account for population structure, genotype principal components 
were computed using the smartpca program in the EIGENSOFT package 
(24). The principal components of genotype were tested for association 
with case status after accounting for study covariates: study, age (10-year 
groupings, matching variable), geographic location (matching variable) 
and DNA source [blood, saliva (Oragene), saliva (mouthwash)]. No prin-
cipal components were strongly associated with case status after con-
trolling for the study covariates. For case status and subtype association 
analyses, we included principal components associated in the full covari-
ate model with P < 0.1.
Statistical analysis
Case–control analyses were conducted for all cases, ER+ cases and ER− 
cases. Among cases with known ER status, case–case analyses were con-
ducted comparing genetic variants between ER− cases and ER+ cases. The 
case–case analysis is important because active mTOR pathway is associ-
ated with lower ER expression levels in ER+ breast tumors (25), and acti-
vated mTOR protein has been more frequently observed in triple-negative 
breast cancer than non-triple negative breast cancer (26). Two approaches 
were used to examine associations of SNPs and breast cancer risk: gene- 
and SNP-based analyses. The gene-based analysis was performed using 
the adaptive rank truncated product (ARTP) test implemented in the R 
package PIGE (27). The ARTP combined the optimal number of most sig-
nificant P-values from among the top 10 SNPs for each gene. We selected 
a set of 10 773 SNPs that were not highly correlated for implementing the 
ARTP method to avoid capturing only a few association signals for some 
genes due to correlations between their top SNPs. One SNP of every pair 
of SNPs with correlation r2 ≥ 0.8 were excluded from the gene-based tests 
using the filter.R2 option in the R package AdaJoint.
SNP-level association analyses were performed for SNPs in genes with 
nominal P < 0.05 in the ARTP tests. We used logistic regression with case 
status as outcome, and an additive model for genotype, adjusting for age 
(10-year groups), study, geographic location, DNA source and principal 
components of the genotypes. P-values were corrected by the Bonferroni 
method for the number of SNPs tested within each gene (Padj). Imputed 
SNPs with minor allele frequency (MAF) <0.02 were excluded due to low 
imputation quality. In addition, to avoid missing any potentially meaning-
ful associations, we report top SNP-level associations for genes with nomi-
nal P ≥ 0.05. P-values for heterogeneity between the risk of ER− and ER+ 
subtypes were calculated using a case–case only logistic regression model.
Statistical analyses were performed using PLINK (version 1.07) 
and R software. Functional follow-up was performed in the ENCODE 
(Encyclopedia of DNA Elements), including HaploReg v3 and RegulomeDB 
databases (28,29).
Results
Table 1 shows the ER status and age distributions of the study 
participants with genotype data (3663 cases and 4687 controls) 
in each study. Overall, 35.6% cases had ER− tumors, with CBCS 
having the highest percentage of young cases.
No gene-level associations were significant after Bonferroni 
corrections for the number of genes tested (n = 61). Table 2 shows 
Figure 1. Overview of the mTOR pathway. 4E-BP1, 4E-binding protein-1; AMP, adenosine monophosphate; AMPK, AMP-activated protein kinase; ATP, adenosine triphos-
phate; eIF-4E, eukaryotic initiation factor-4E; ER, estrogen receptor; IRS, insulin receptor substrate; MAPK, mitogen-activated protein kinase; MLST8, mTOR-associated 
protein, LST8 homolog; mSIN1, mammalian stress-activated protein kinase interacting protein 1; PGF, placental growth factor; PRAS40, proline-rich Akt substrate 
40 kDa; Proctor, protein observed with Rictor; PTEN, phosphatase and tensin homologue; Raf, Raf-1 proto-oncogene, serine/threonine kinase; Raptor, regulatory associ-
ated protein of mTOR; Rictor, rapamycin-insensitive companion of mTOR; S6, 40S ribosomal protein; S6K1, S6 kinase 1; STK11, serine/threonine kinase 11; TSC, tuber-
ous sclerosis complex.
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genes that had a nominal P value <0.05 in relation to breast can-
cer in the gene-level analysis. Tuberous sclerosis 2 (TSC2) and 
B-Raf proto-oncogene, serine/threonine kinase (BRAF) were 
associated with all breast cancer; TSC2 with ER+ tumors; and 
BRAF, placental growth factor (PGF), and mitogen-activated pro-
tein kinase 3 (MAPK3) with ER− tumors. Comparing ER− cases 
with ER+ cases, MAPK3 and ribosomal protein S6 kinase, 70 kDa, 
polypeptide 2 (RPS6KB2) had a nominal P < 0.05.
Table 3 shows gene-wide significant variants from the SNP-
level association analysis with all, ER+ and ER− breast cancer. 
Among the nominally significant genes, the variant allele of 
TSC2 rs181088346 was significantly associated with a decrease 
in overall breast cancer risk [odds ratio (OR)  =  0.77 for each 
copy of the A  allele, 95% confidence interval (CI)  =  0.65–0.88, 
Padj = 0.035]. Similar ORs (0.73 and 0.88) were observed for ER+ 
cases and ER− cases compared with controls, respectively. BRAF 
rs114729114 was associated with increased risk of all breast 
cancer (OR = 1.53 for each copy of the T allele, 95% CI = 1.24–
1.91, Padj  =  0.012), with stronger associations with ER− tumors 
(OR  =  2.03, 95% CI  =  1.50–2.76, Padj  =  0.001), than ER+ tumors 
(OR = 1.44, 95% CI = 1.10–1.87, Padj = 0.79; P-heterogeneity = 0.006). 
PGF rs11542848 at 5′-untranslated region (OR = 1.38 for each copy 
of the T allele, 95% CI = 1.15–1.66, Padj = 0.049) and an intron SNP 
rs61759375 (OR = 1.34 for each copy of the T allele, 95% CI = 1.14–
1.57, Padj = 0.032), as well as MAPK3 rs78564187 (intron, OR = 1.26 
for each copy of the A allele, 95% CI = 1.11–1.43, Padj = 0.006), were 
also associated with an increase in ER− breast cancer risk. In 
the case–case analysis comparing ER− and ER+ cases, a synony-
mous coding SNP, rs35363135, had the lowest P value in RPS6KB2 
(OR = 1.18 for each copy of the A allele, 95% CI = 1.05–1.31, nomi-
nal P = 0.0038, Padj = 0.06; data not shown).
Top SNPs in non-significant genes are listed in Supplementary 
Table 2, is available at Carcinogenesis Online. Multiple signals were 
observed for phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunits: PIK3CA, PIK3CB, PIK3R1 and PIK3R3 (all cases 
versus controls); RPS6KA2 (all cases and ER− cases versus con-
trols) and regulatory associated protein of MTOR, complex 1 
(RPTOR; all cases and ER+ cases versus controls), protein kinase, 
adenosine monophosphate–activated and gamma 2 non-cata-
lytic subunit (PRKAG2; ER− cases versus controls). Several SNPs 
in PRKAG2, RPS6KA2 and RPTOR were observed in the case–case 
comparison. None of the SNPs reported in Supplementary 
Table  2, is available at Carcinogenesis Online, were statistically 
significant after a Bonferroni correction for total number of 
tested SNPs.
Discussion
In the AMBER consortium study of breast cancer in AA women, 
several genes in the mTOR pathway, namely, TSC2, BRAF, PGF 
and MAPK3, were associated with overall risk of breast cancer 
and subtypes defined by ER status. In these genes, specific SNPs 
associated with breast cancer risk were identified after correct-
ing for multiple comparisons at the gene level. To our knowl-
edge, this is the first study that systematically examined the 
association of mTOR pathway genes with breast cancer risk in 
AA women, a population with higher proportions of obesity and 
ER− breast cancer than white women.
Among the significant SNPs in our results, several appear to be 
in regions with important regulatory functions (Supplementary 
Table 3, is available at Carcinogenesis Online). PGF rs11542848 is 
located in a region with transcriptional promoters for breast 
myoepithelial cells. In PGF, the other significant SNP rs61759375 
maps to a region containing transcriptional enhancers, and 
its tagged SNP rs11542848 is located in the promoter region of 
5′-untranslated region. In addition, MAPK3 rs78564187 also tags 
several SNPs that overlap enhancer binding sites. Also, our case–
case analysis showed that a synonymous coding SNP rs35363135 
in RPS6KB2 was associated with ER− breast cancer. The SNP 
is located in a region containing active promoters and likely 
Table 1. Case–control status and age distribution in the studies of the AMBER consortium
Case–control status and variable CBCS WCHS BWHS MEC Total (AMBER consortium)
Breast cancer casesa 1408 821 901 533 3663
 ER+ 741 (56.7)b 435 (72.5) 498 (68.1) 309 (69.6) 1983 (64.4)
 ER− 595 (43.3) 165 (27.5) 233 (31.9) 135 (30.4) 1098 (35.6)
Controls 615 834 2249 989 4687
Age (year)
 <50 961 (47.5) 644 (38.9) 1178 (37.4) 25 (1.6) 2808 (33.6)
 ≥50 1062 (52.5) 1011 (61.1) 1972 (62.6) 1497 (98.4) 5542 (66.4)
Values in parentheses are percentages.
aFive hundred and eighty-two cases (15.9%) in AMBER had unknown ER status.
bPercentages of all breast cancer cases with known ER status.
Table 2. Genes in the mTOR pathway with nominally significant P-values in case–control and case–case analyses
Nominal P-value
Gene Number of SNPs tested All cases versus controls
ER+ cases versus 
controls
ER− cases versus 
controls
ER− cases versus ER+ 
cases
TSC2 128 0.009 0.012 0.99 0.56
BRAF 115 0.046 0.47 0.004 0.45
PGF 111 0.63 0.93 0.008 0.32
MAPK3 19 0.69 0.93 0.012 0.029
RPS6KB2 17 0.73 0.69 0.45 0.010
Nominal P < 0.05 are in bold. All Bonferroni corrected P > 0.05.
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affecting transcription factor binding (RegulomeDB score = 2b). 
RPS6KB2 encodes a member of the S6K1 family of serine/threo-
nine kinases, which can modify ER expression (30).
Data on the mTOR pathway SNPs in relation to breast can-
cer risk or subtypes are very limited. One study examined 
three functional SNPs of the late endosomal LAMTOR complex 
(LAMTOR2 and LAMTOR3), which is a key protein for the crosstalk 
between the mTOR and the MAPK pathways, among European 
women (10). This study found that in a small case-only analysis 
(296 cases), variants in LAMTOR3 rs148972953 were associated 
with higher proportions of ER− and progesterone receptor nega-
tive breast cancers. In a subsequent larger case–control analysis 
(2715 cases and 5216 controls), however, the SNP was not asso-
ciated with breast cancer risk (10). Although LAMTOR3 was not 
included in our gene selection, we observed two SNPs in MAPK3 
and BRAF, a member of the Raf family and main activator of 
the MAPK pathway, were associated with a modest increase in 
ER− breast cancer risk in AMBER. Another study examined six 
tag SNPs in TSC1 and TSC2 in 1137 breast cancer cases, with 
the majority being Caucasians (78%). Patients with the TSC1 
rs1073123 variant were less likely to have ER− breast cancer 
than ER+ breast cancer (OR = 0.39, 95% CI = 0.14–1.08, P = 0.06; 
homozygous variant versus common allele) (11). In AMBER, we 
observed a non-significant inverse association for this SNP com-
paring ER− cases to ER+ cases (OR = 0.94 for each copy of the var-
iant allele, 95% CI = 0.83–1.07, nominal P = 0.39; data not shown). 
The mechanisms of TSC1 and TSC2 influencing ER expression 
may involve the inhibition of ER-α functions by tuberin, the 
protein product of TSC2 (31). The significant SNPs in our results 
have not been reported in Caucasian or Asian women for breast 
cancer risk or subtypes.
Current literature suggests that mTOR pathway genes 
involved in carcinogenesis may differ by cancer site. A number 
of SNPs in RPTOR and AKT3 have been linked to risk of bladder 
cancer and renal cell carcinoma, respectively, in non-Hispanic 
whites (32,33). The reported SNPs in these two genes were not 
significantly associated with breast cancer risk in AMBER (nomi-
nal P > 0.05; data not shown), although our exploratory analysis 
suggested that a number of SNPs in RPTOR may be potentially 
important for overall and ER+ breast cancer risks in AA women. 
However, for colorectal cancer, significant SNPs were observed 
in various genes including MTOR, PIK3CA, PRKAG2, PTEN, STK11, 
TSC1 and TSC2 (34). The variant in PRKAG2 rs4128396 was associ-
ated with an increased risk of rectal cancer (OR = 1.33, 95% CI = 
1.09–1.63; AC/CC versus AA genotypes) (34). In AMBER, however, 
this SNP was associated with a decrease in ER− breast cancer 
risk (OR = 0.76 for each copy of the variant allele, 95% CI = 0.59–
0.97, nominal P = 0.028; data not shown). These observations 
require validation using populations with the same ancestral 
backgrounds. From a biological point of view, the mTOR path-
way can be signaled by multiple factors (growth factors, nutri-
ents and energy), and all cells may not be equally responsive 
to these factors. Thus, cells in distinctive tissues or organs may 
have different requirement for mTOR (8).
The large sample size enabled analysis of risk for overall 
breast cancer, as well as for ER+ and ER− cancer separately. 
Furthermore, this was a more comprehensive evaluation of 
mTOR pathway SNPs than in most previous studies. However, 
several limitations should be noted. First, all the significant 
SNPs identified were imputed in either the CBCS/WCHS/BWHS 
combined genotyping project, the MEC genotyping project, or 
both. These imputed SNPs have high accuracy [imputation r2 ≥ 
0.9, except for TSC2 rs181088346 and PGF rs61759375 (r2 = 0.802 
and 0.884, respectively, in the MEC genotyping project) and BRAF Ta
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rs114729114 (r2 = 0.728 in the CBCS/WCHS/BWHS genotyping 
project), Table 3]. To further validate our findings, we performed 
association analyses among the individuals with a posterior 
genotype probability ≥0.9 at the untyped SNPs in the CBCS/
WCHS/BWHS project (35). There was no material difference 
in risk estimates between all individuals and those with high 
certainty of the imputed genotype (Supplementary Table 4, is 
available at Carcinogenesis Online). Although the quality of these 
imputed SNPs was very high, results from these imputed SNPs 
warrant further confirmation by genotyping. Second, we did not 
have data on human epidermal growth factor receptor 2 in a suf-
ficient number of cases for specific analyses of triple-negative 
breast cancer or other subtypes dependent on that molecular 
marker. Lastly, our findings require validation, as the gene-level 
associations were not significant after correction for multiple 
tests.
In conclusion, in this systematic assessment of genetic 
variation in the mTOR pathway, we identified several genes 
that are associated with risk of breast cancer overall (TSC2 
and BRAF), ER+ tumors (TSC2) and ER− tumors (BRAF, PGF 
and MAPK3). Our findings suggest that the mTOR pathway 
may be important in breast carcinogenesis in AA women. 
Future studies on genetic variants in the mTOR pathway with 
breast cancer risk and subtypes should involve obesity phe-
notypes to reveal potential gene–environment interactions. 
In addition, direct assessment of mTOR activities, for exam-
ple, mTOR protein expression in tumor tissues, can provide 
a better understanding of underlying mechanisms of obe-
sity regarding energy imbalance in relation to breast cancer 
subtypes.
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